Perspective: plasticity, the enemy of the good

Sarah Yvonnet¹,², Anouk Barberousse¹, Alexandre E. Escargueil²

¹Sorbonne Université, CNRS, Laboratory Sciences, Normes, Démocratie (SND), Paris F-75005, France.
²Sorbonne Université, INSERM, Laboratory Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine, CRSA, Paris F-75012, France.

Correspondence to: Dr. Alexandre E. Escargueil, Sorbonne Université, INSERM, Laboratory Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine, CRSA, Paris F-75012, France. E-mail: alexandre.escargueil@inserm.fr

How to cite this article: Yvonnet S, Barberousse A, Escargueil AE. Perspective: plasticity, the enemy of the good. Cancer Drug Resist 2019;2:351-5. http://dx.doi.org/10.20517/cdr.2019.23

Received: 3 Apr 2019 Accepted: 7 May 2019 Published: 19 Jun 2019

Science Editor: Godefridus J. Peters Copy Editor: Cai-Hong Wang Production Editor: Huan-Liang Wu

Abstract
Plasticity is an important feature of modern cancer research. However, the level at which we should consider it remains an open question. Such debate is not new in the field of cancer and can be exemplified by the different models explaining carcinogenesis. Those models mostly explain cell transformation through the deregulation of the internal circuitry. In the last years, those models dramatically increased our knowledge and led to a series of short-term successes in terms of therapeutics. However, cancer drug resistance inevitably arises. Recently, studies on the so-called tumor microenvironment enriched the cell-centered perspective but it also enlarged the complexity of cancer etiology in particular for advanced diseases. Here, we suggest that the plastic and multi-sites specific nature of cancer combined with our incapacity to promise cure should push towards a new perspective where early clinical actions, instead of late ones, should be heralded as the priority of cancer research and care.

Keywords: Resistance, plasticity, metastasis, timeline, clinical action

Plasticity is becoming a key feature of Cancer research and its understanding is raising new challenges for caregivers and decision makers. However, the level to which we shall consider plasticity (e.g., tumor or cancer cell levels) remains a questionable issue that might yet have important consequences in terms of drug development, cancer patients’ care and future medical interventions. Such a debate is not particularly new. Cancer research is indeed a field particularly prone to the existence of different models. This might be exemplified with two models made to explain the etiology of the disease: the “multigenic and multiphasic model of cancer”⁴ and the “epigenetic progenitor model of cancer”⁵. The former one relies on the mutational...
activation of oncogenes and inactivation of tumor suppressor genes. In that model, oncogenes and tumor suppressor genes are particularly important because they can be thought as highly connected nodes in the genetic network capable of integrating signals controlling cell cycle and cell death\cite{4,5}. Tumor formation then requires the accumulation of additional mutations determining the biological features of the tumor\cite{1}.

In the “epigenetic progenitor model of cancer”, it has been suggested that tumorigenesis first relies on an abnormality of the epigenetic network of progenitor cells that precedes mutations in tumor suppressor genes and oncogenes\cite{6}. This is followed by a general epigenetic and genetic instability that is designing the evolution of the tumor mass\cite{6,7}. Interestingly, both models share a global cell centered perspective [Figure 1]. Indeed, while the “multigenic and multiphasic model” describes the etiology of the disease through a succession of genes mutations\cite{4}, the “epigenetic progenitor model” focuses on gene modulation events including modifications like gene hypomethylation or hypermethylation as the initial disruptive step leading to the development of the neoplasm\cite{6}. Those two models however regard cancer as a disruption of the normal cell cycle and are grounded on the importance of the cell transformation through the dysregulation of its own internal mechanisms. Those two different models share so a common perspective that was described by Bertolaso as the “cell centered perspective”\cite{3}.

The accumulation of complications: Each of the two models within the “cell-centered perspective” tends to identify new molecular and intracellular pathways and processes involved in cancer progression and the occurrence of new tumor cell capacities including those involved in drug resistance. This leads to an increased knowledge but also to an outstanding number of possible elements involved in the etiology of the pathology. So, while biologists collect still more data, it is now difficult to make a clear sense out of this overwhelming set of information. Already, in 2006, Hornberg et al.\cite{8} stated that: “Although knowledge of the molecular cell biology of cancer is enormous, at the same time, the emerging complexity of the entire ‘cancer system’ overwhelms us, leaving an enormous gap in our understanding and predictive power”. This “gap” between the accumulation of molecular knowledge and the understanding of the disease is now becoming problematic, because despite the enormous resources that are spent each year, cancer research did not provide a clear and actionable insight into the way the disease begins, progresses and reaches a highly plastic and heterogeneous structure in advanced diseases\cite{12}. Therefore, it seems that the cell centered perspective is now confronted to what the philosopher Bertolaso called “The wall of complication” meaning that despite of the amount of informations, biologists are struggling to get a simpler and more comprehensive view of cancer\cite{3}.

Time for a change? In front of such a “wall of complication” faced by the cell-centered perspective, biologists\cite{9,10} first proposed to look at the problem in a different way: “There is not solely a matter how to integrate all available knowledge in such a way that we can still deal with complexity, but we must be aware that a deeply transformation of the currently accepted paradigm is urgently needed”\cite{10}. One of the justifications for such a change of perspective is that cancer cells are, by definition, not isolated. They are always in interactions with normal cells within the diseased tissue\cite{11}. Tenants of a change proposed so that rather asking how normal cells can be transformed into cancerous cells, biologists should ask how multicellular tissues can be turned into tumors\cite{6,13}. Here, cancer should be thought as the loss of tissue function and organization that is usually maintained by the interplay between parenchymal cells and their microenvironment\cite{11}. In that context, the change of perspective mostly consists in addressing questions about carcinogenesis at a different biological level such as the potential role played by the microenvironment in cancer promotion and progression [Figure 1] and whether the microenvironment could be a therapeutic target in order to cure cancer\cite{13,11}. However, while knowledge is still growing and data accumulating, demonstrating each day more complexity, we should now ask whether this is not the time for moving again to a new perspective. In metastatic disease, the microenvironment is indeed highly versatile and is capable to select for specific clones turning what was initially thought as a unique disease to a multi-sites specific disease\cite{12-16}. In such a model, the “survival of the fittest” becomes the rule of cancer evolution and our
promise to cure all cancer through new drugs development remains very unlikely and, in a way, shallow [Figure 1]. The “survival of the fittest” model, where cancer cells’ fitness mostly relies on their interactions with their surrounding environment, might so better define the process of tumorigenesis and its associated plasticity in terms of adaptive behaviors. Importantly, its conceptualization should also warn us on our real ability to act efficiently on such an “irrational” behavior of human cells. In other words, tumor plasticity might render our quest to cure cancer useless because cancer drug resistance will inevitably arise [Figure 1]. This vicious circle, made of short-term success and failure, can broadly be illustrated with the resistances that are developed in response to the use of tyrosine kinase inhibitors [17-19]. Thus, admitting our inability to treat such highly advanced diseases might help us to redirect the available resources to develop and clinically validate new strategies for either detecting early cancer where clinical actions are efficient or assessing the risk of recurrence of early diagnosed neoplasms [20,21]. In that perspective, the characterization of the precise timeline of cancer dissemination might help to focus researches and resources towards the detection of early disseminating neoplasms with poor clinical outcome [22,23]. The recent success obtained against Human Papilloma Virus-induced cervical cancer might, in a way, highlight the need to precisely characterize timelines of disease development and dissemination to prevent and control cancer [24]. However, to be entirely efficient, prophylactic and preventive actions against cancer need to be a call to action for the world health
community to facilitate access to new preventive and screening technologies and to increase their acceptance by the global communities.

This change of perspective will certainly not solve all the unanswered questions regarding cancer. It also does not mean that a cell-centered perspective has to be dropped out, or that it does not work as it led to many successes\textsuperscript{[25]}. However, it may contribute to make sense of "the vast body of essentially incoherent phenomena that constituted cancer research\textsuperscript{[2]} and to focus cell centered researches to rare neoplasms where either early detection is not possible or treatment not, or poorly, accessible. Obviously, this change of perspective should be part of a long term action involving not only biologists or clinicians but also human, political and public health sciences. In such a perspective, non-biologist inputs will strikingly be required to foster dialogue between cancer biology, society and decision makers and to challenge certitudes [Figure 1]. Accordingly, in a recent article, Laplane and colleagues underline the need to re-implement philosophy in sciences where philosophy might contribute to “the clarification of scientific concepts, the critical assessment of scientific assumptions or methods, the formulation of new concepts and theories, and the fostering of dialogue between different sciences, as well as between science and society”\textsuperscript{[26]}. The aim here is that, maybe, biologists have the opportunity to switch to a different perspective that could open up new complementary axes of research that hopefully would break the scheme of the short-term success before facing complications and cases of resistance\textsuperscript{[3]}.

DECLARATIONS
Authors’ contributions
Writing, review, and/or revision of the manuscript: Escargueil AE, Yvonnet S, Barberousse A
Conception and design of the perspective: Escargueil AE, Yvonnet S, Barberousse A

Availability of data and materials
Not applicable.

Financial support and sponsorship
Sarah Yvonnet is supported by a fellowship from the PhD program in Oncology of the “Institut Universitaire de Cancérologie”, Sorbonne Université.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Escargueil AE, Prado S, Dezaire A, Clairambault J, Larsen AK, et al. Genotype - or phenotype-targeting anticancer therapies? Lessons from tumor evolutionary biology. Curr Pharm Des 2016;22:6625-44.
2. Weinberg RA. Coming full circle-from endless complexity to simplicity and back again. Cell 2014;157:267-71.
3. Bertolaso M. Philosophy of Cancer. 1st ed. Netherlands: Springer; 2016.
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
5. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
6. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
7. Heng HH, Bremer SW, Stevens JB, Karen JY, Liu G, et al. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol 2009;220:538-47.
8. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. Cancer: a systems biology disease. Biosystems 2006;83:81-90.
9. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
10. Bizzarri M, Cucina A. Tumor and the microenvironment: a chance to reframe the paradigm of carcinogenesis? Biomed Res Int 2014;2014:934038.
11. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000;6:324-9.
12. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010;20:68-80.
13. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
14. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306-13.
15. Korolev KS, Xavier JB, Gore J. Turning ecology and evolution against cancer. Nat Rev Cancer 2014;14:371-80.
16. Maddipati R, Stanger BZ. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov 2015;5:1086-97.
17. Ramírez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun 2016;7:10690.
18. Ortiz-Cuarán S, Scheffler M, Plenker D, Dahmen L, Scheel AH, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation egfr inhibitors. Clin Cancer Res 2016;22:4837-47.
19. Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and combination therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res 2018;24:6195-203.
20. Tie J, Wang Y, Tomasetti C, Li L, Springer S, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346ra92.
21. Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A 2017;114:10202-7.
22. Leung ML, Davis A, Gao R, Cassent A, Wang Y, et al. Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. Genome Res 2017;27:1287-99.
23. Reiter JG, Makohon-Moore AP, Gerold JM, Bozie I, Chatterjee K, et al. Reconstructing metastatic seeding patterns of human cancers. Nat Commun 2017;8:14114.
24. Small W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, et al. Cervical cancer: a global health crisis. Cancer 2017;123:2404-12.
25. Kan, Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010;466:869-73.
26. Laplane L, Mantovani P, Adolphs R, Chang H, Mantovani A, et al. Why science needs philosophy. Proc Natl Acad Sci U S A 2019;116:3948-52.